An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Key facts
- Where
- Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Langfang, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, and Zhengzhou, ChinaSee the 20 sites
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
- Peking University Third HospitalBeijing, ChinaTaking people
- The First Bethune Hospital of Jilin UniversityChangchun, ChinaTaking people
- West China Hospital of Sichuan UniversityChengdu, ChinaTaking people
- Guangdong Provincial People's HospitalGuangzhou, ChinaTaking people
- Harbin Medical University Cancer HospitalHarbin, ChinaTaking people
- Shandong Cancer HospitalJinan, ChinaTaking people
- Cancer Hospital Chinese Academy of Medical SciencesLangfang, ChinaTaking people
- The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaTaking people
- The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
- Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaTaking people
- Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
- Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment CenterTianjin, ChinaTaking people
- Tianjin Cancer HospitalTianjin, ChinaTaking people
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & TechnologyWuhan, ChinaTaking people
- Xiehe Hospital, Tongji Medical College Huazhong University of Science & TechnologyWuhan, ChinaTaking people
- The First Affiliated Hospital of Xian Jiao Tong UniversityXi'an, ChinaTaking people
- Yantai Yu Huangding HospitalYantai, ChinaTaking people
- Henan Cancer HospitalZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07200375
- Record updated
- 5 November 2026
- Original description
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).Read full original descriptionShow less
Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Inclusion: Histologically confirmed R/R DLBCL after one line of systemic therapy; Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment.
Exclusion: Participants who currently participate in or plan to participate in any interventional clinical trial.